GA
FLNA

GoalVest Advisory’s Filana Therapeutics FLNA Stock Holding History

GoalVest Advisory’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-971
Closed -$28.6K – 427
2024
Q3 		$28.6K Hold
971
– – 0.01% 235
2024
Q2 		$12K Buy
971
+225
+30% +$4.74K ﹤0.01% 266
2024
Q1 		$15.1K Hold
746
– – 0.01% 290
2023
Q4 		$16.8K Hold
746
– – 0.01% 223
2023
Q3 		$12.4K Hold
746
– – 0.01% 253
2023
Q2 		$18.3K Hold
746
– – 0.01% 207
2023
Q1 		$18K Buy
746
+235
+46% +$6.51K 0.01% 166
2022
Q4 		$15.1K Buy
511
+4
+0.8% +$144 0.01% 172
2022
Q3 		$21K Buy
507
+12
+2% +$324 0.01% 154
2022
Q2 		$13K Sell
495
-877
-64% -$22.1K 0.01% 243
2022
Q1 		$51K Buy
+1,372
New +$58.1K 0.03% 153

Other funds holding FLNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

GoalVest Advisory's FLNA Position: Q4 2024 in Review

GoalVest Advisory sold out of Filana Therapeutics (FLNA) in Q4 2024, closing a stake of 971 shares — an estimated $28.6K sold.

GoalVest Advisory first reported a position in FLNA in Q1 2022 and held it in 11 quarters. The position peaked at $51K in Q1 2022. 137 funds tracked by Wall St. Rank hold FLNA as of Q4 2024.

  • GoalVest Advisory reported no remaining Filana Therapeutics position as of Q4 2024 after selling out during the quarter.
  • GoalVest Advisory sold 971 Filana Therapeutics shares in Q4 2024, an estimated $28.6K.
  • GoalVest Advisory first reported a position in Filana Therapeutics in Q1 2022 and held it in 11 quarters.
  • GoalVest Advisory's Filana Therapeutics position peaked at $51K in Q1 2022.
  • 137 funds tracked by Wall St. Rank held Filana Therapeutics as of Q4 2024.

Based on GoalVest Advisory's 13F filing for Q4 2024, filed 17 Jan 2025.